The Pharma Data

DECEMBER 10, 2020

–( BUSINESS WIRE )– ImmunityBio , a privately-held immunotherapy company, today announced its COVID-19 vaccine candidate protected nasal and lung airways of non-human primates against coronavirus (SARS-CoV-2) in a challenge study. 11, 2020 02:48 UTC. CULVER CITY, Calif.–(

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

Vial

DECEMBER 11, 2023

Despite advances in clinical research, there remain significant challenges as only 20% of HCV cases are diagnosed, and of these, only 15% receive treatment. The Food and Drug Administration (FDA) approved and recommended dozens of small-molecule drugs. Two highly effective pan-genotypic DAAs are used worldwide.

Clinical Research 52

Clinical Research Therapies Research Vaccine 52

The Pharma Data

DECEMBER 18, 2020

Food and Drug Administration issued an emergency use authorization (EUA) for the second vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The emergency use authorization allows the Moderna COVID-19 Vaccine to be distributed in the U.S. Hahn , M.D.

Vaccine 52

Vaccine FDA Clinical Trials FDA Approval 52

The Pharma Data

OCTOBER 26, 2020

FDA Actions. FDA Approval: Last week the FDA approved Veklury (remdesivir) for the treatment of COVID-19 requiring hospitalization in adults and pediatric patients (12 years of age and older). Testing Therapies, Antivirals and Vaccines. The approval marks the first drug approved by the U.S.

Vaccine 52

Vaccine FDA Approval FDA Clinical Trials 52

The Pharma Data

DECEMBER 11, 2020

FDA authorizes COVID-19 mRNA vaccine for emergency use; companies are prepared to deliver first doses in the U.S. In collaboration with Operation Warp Speed, Pfizer and BioNTech, as well as other vaccine companies are expected to deliver hundreds of millions of vaccine doses to Americans by the end of 2021.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

DECEMBER 10, 2020

. Data from 43,448 participants, half of whom received BNT162b2 and half of whom received placebo, showed that the vaccine candidate was well tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection 7 days or more after the second dose. Jansen, Ph.D.,

Vaccine 52

Vaccine Trials Clinical Trials Therapies 52

NIH Director's Blog: Drug Development

FEBRUARY 16, 2021

Yet the quest to save more lives from COVID-19 isn’t even close to being finished, and researchers continue to work intensively to develop new and better treatments. Vaccines Working Group : Accelerates the evaluation of vaccine candidates.

Clinical Trials 52

Clinical Trials Hospitals Vaccine Trials 52

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) to begin a Phase I clinical trial of hAd5-COVID-19, the company’s novel COVID-19 vaccine candidate that targets both the inner nucleocapsid (N), engineered to activate T cells, and outer spike (S) protein, engineered to activate antibodies against the coronavirus (SARS-CoV-2).

Vaccine 52

Vaccine Trials FDA Clinical Trials 52

The Pharma Data

NOVEMBER 12, 2020

José Baselga, Executive Vice President, Oncology R&D, said: “Since the beginning of the year, AstraZeneca has been committed to doing everything we can to respond to COVID-19, including investigating existing medicines as potential treatments. Related Articles: Calquence (acalabrutinib) FDA Approval History. J Hematol Oncol.

Trials 52

Trials Clinical Trials Immune Response FDA Approval 52

Agency IQ

DECEMBER 1, 2023

FDA’s guidance on developing products to prevent or treat Covid-19 Of the five guidance documents that received an extension, one addresses the development of drugs and biological products for Covid-19. It also stated that companies should consider whether an investigational product might interact with an administered vaccine for Covid-19.

FDA 40

FDA Clinical Trials Vaccine Trials 40

The Anticancer Fund

JUNE 23, 2023

Treatment of immunocompetent mice with canagliflozin was associated with reduced tumour growth, to the same extent as treatment with immune checkpoint inhibitors. Additionally, the D+C had a higher rate of toxicity and 10 patients (24%) discontinued disulfiram treatment because of adverse effects. months, SOC vs D+C).

Drugs 52

Drugs Trials Clinical Trials Treatment 52

Drug Discovery World

JULY 8, 2024

While mRNA vaccines and RNA interference therapies have garnered much attention, a new class of RNA therapeutics known as aptamers is gaining momentum, particularly to address acute diseases. RNA vaccines: encoding linear information The first category of RNA therapeutics is probably the most well recognised in medicine – mRNA vaccines.

RNA 148

RNA Small Molecule Vaccine FDA Approval 148

The Pharma Data

JUNE 18, 2021

First approval of a conjugate vaccine that helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia, 1,2,3,4,5,6,7 including seven responsible for 40% of pneumococcal disease cases and deaths in the U.S. Following today’s FDA approval, the U.S.

Vaccine 52

Vaccine FDA Approval FDA Disease 52

The Pharma Data

MARCH 16, 2021

Durability: 1,2 Robust joint and skin response rates and mean improvements from baseline in outcome measures were maintained through two years, and approximately 90 percent of patients randomized to TREMFYA q4w or q8w continued treatment with TREMFYA through Week 100. TREMFYA was approved in the U.S.

Treatment 52

Treatment Pharmacokinetics Disease Pharmaceutical Companies 52

Drug Discovery World

MAY 11, 2023

Gene-based therapeutics and vaccines hold immense potential for more efficient and personalised treatment and prevention of complex diseases. In these cases, injection of the viral vector vaccines induced the production of antibodies recognising platelet factor 4 (PF4) found on patients’ platelets 1.

Production 130

Production Vaccine Immune Response Therapies 130

Codon

JULY 14, 2024

The transfusion of platelets thus seems like an obvious treatment to stem bleeding. Despite the initial promise of PFCs and FDA approval of a product called Fluosol-DA in 1989, PFCs have many drawbacks. As a clot forms, liquid blood becomes a solid plug that can stop bleeding in a matter of minutes.

Production 118

Production Clinical Trials Trials Therapies 118

Drug Discovery World

AUGUST 1, 2023

In terms of breakthroughs and results, in July 2023, DDW reported that Alnylam Pharmaceuticals has revealed results from its Phase I study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension.

RNA 130

RNA Vaccine Drugs Disease 130

The Pharma Data

DECEMBER 31, 2020

Moderna and Pfizer’s COVID-19 Vaccines Roll Out in Early Phase. Food and Drug Administration (FDA) issued Emergency Use Authorization for two COVID-19 vaccines: Pfizer-BioNTech’s BNT162b2 and Moderna’s mRNA-1273. In studies, the vaccines were found to be 94% to 95% effective in preventing COVID-19 disease.

FDA Approval 52

FDA Approval Vaccine FDA Immune Response 52

The Pharma Data

APRIL 4, 2023

First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. This indication is approved under accelerated approval based on tumor response rate and durability of response.

FDA Approval 40

FDA Approval Treatment FDA Therapies 40

The Pharma Data

NOVEMBER 20, 2020

Food and Drug Administration (FDA). The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as casirivimab and imdevimab have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load.

Therapies 52

Therapies FDA Clinical Trials Hospitals 52

The Pharma Data

APRIL 27, 2021

at CER driven by growth drivers Dupixent ® and Vaccines. Vaccines up 5.3%, driven by PPH franchise and demand for influenza vaccines in southern hemisphere. Vaccines delivered growth in its core segments. reflecting lower treatment compliance during the COVID-19 pandemic. Q1 2021 sales increase of 2.4% In the U.S.

Vaccine 52

Vaccine Production FDA FDA Approval 52

The Pharma Data

NOVEMBER 21, 2020

21, 2020 /PRNewswire/ — First treatment of any kind to have prospectively confirmed and statistically significant anti-viral activity against SARS-CoV-2. Food and Drug Administration (FDA). TARRYTOWN, N.Y. , Authorized for recently diagnosed, mild to moderate COVID-19 in high-risk patients. government allocation program.

FDA 40

FDA Clinical Trials Hospitals Government 40

The Pharma Data

OCTOBER 26, 2020

The treatment induced HPV-specific T-cell responses and was associated with increased levels of immune cell infiltration in the tumors and expression of genes associated with activation of the immune system. An overall response rate of 23.5% and a median PFS of 5.6

Vaccine 52

Vaccine Virus Trials Treatment 52

The Pharma Data

FEBRUARY 24, 2022

If the EC grants the variation, the decision will be immediately applicable to all 27 EU member states, making booster vaccines available to everyone 12 years and older. . The COVID-19 vaccine booster for individuals 12 through 15 years of age was already granted Emergency Use Authorization by the U.S. and Europe.

Vaccine 52

Vaccine FDA Small Molecule Immune Response 52

Codon

APRIL 23, 2023

Unfortunately, they can also trigger immune responses, and they are not super efficient at gene-editing some parts of the brain. These ribonucleoproteins also caused a lower immune response compared to the viruses, and are much easier to make in the lab. Promising new malaria vaccine for kids approved in Ghana.

Vaccine 52

Vaccine DNA Virus Engineering 52

Codon

APRIL 23, 2023

Unfortunately, they can also trigger immune responses, and they are not super efficient at gene-editing some parts of the brain. These ribonucleoproteins also caused a lower immune response compared to the viruses, and are much easier to make in the lab. Promising new malaria vaccine for kids approved in Ghana.

Vaccine 52

Vaccine DNA Virus Engineering 52